LONDON–(BUSINESS WIRE)–  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari

LONDON–(BUSINESS WIRE)–  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari

DENVER–(BUSINESS WIRE)—- $BURU #LYOCON–NUBURU, Inc. (NYSE American: BURU) (“NUBURU” or the “Company”) today highlighted the completion of its acquisition of a 70% controlling interest in TEKNE S.p.A. (“TEKNE”), its previously reported stockholders’ equity position, and its operating priorities as the Company’s NYSE American equity compliance plan period approaches its October 29, 2026 deadline. The completed TEKNE acquisition advances NUBURU’s transformation into an integrated defense and security technology

WEST PALM BEACH, Fla.–(BUSINESS WIRE)–HighPost Capital, LLC (“HighPost”), a leading private investment firm focused on visionary companies and founders, today announced that Ron Sylvestri has joined the firm as Managing Director, Marketing. In this role, he will support the firm’s marketing and capital formation efforts, expanding and deepening HighPost’s relationships with institutional investors globally. He will report to David Moross, Chairman and Chief Executive Officer of HighPost. Mr.

ESCONDIDO, Calif.–(BUSINESS WIRE)–Enthorin Therapeutics, LLC today announced that it has entered into an option-to-license agreement with Rumi Therapeutics for ENT-7340, Enthorin’s IND-enabled phosphodiesterase 2A (PDE2A) inhibitor being developed for Fragile X syndrome (FXS) and other intellectual and developmental disabilities. Under the agreement, Rumi Therapeutics will assume responsibility for development of ENT-7340, which will be advanced by Rumi under the development name RTX-7340. En

MINNEAPOLIS–(BUSINESS WIRE)–Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Paul Friel to its Board of Directors. The appointment comes as Vergent prepares for a potential New Drug Application (NDA) filing and commercialization of abenacianine in lung cancer surgery, while continuing to advance the technology across additional oncology indications. Mr. Friel brings more than 30 years of commer

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.